arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

STANDARD BIOTOOLS INC.

LAB
$0.62 ▲ +0.01 (+1.76%) at close
Industrials ·Laboratory Analytical Instruments ·USLaboratory Analytical Instruments
18 Visible periods
31 Metrics
Peer-ranked Benchmarks
Price Chart
19
Health
Poor
Bearish
auto_awesome

Analytical Summary

STANDARD BIOTOOLS INC. faces fundamental challenges with weakness in Profit Margin (%) and Operating Margin (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $236.6M
Dividend Yield —
Revenue Growth -51.1% ↘
Op. Margin -129.2% ↘
ROIC -15.8% ↗
FCF / Share $-0.22 ↗
Trailing P/E —
Price / Book 0.6x
FCF Yield —
Debt / Equity —
info Valuation on last close. End-of-day price, Nov 5, 2026.

18-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$85.33M
↓ -51.1% —
Net Income Profit after all expenses
$-74.90M
↑ +46.1% —
Operating Margin Operating profit as % of sales
-129.2%
↓ -28.6% 1th
FCF / Share Free cash flow per share
$-0.22
↑ +49.6% —
Long-Term Debt Long-term obligations
$299.00K
↓ -99.5% —
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile

Health Breakdown

Profitability ↓
2
Returns ↑
29
Financial Health ↓
1
Cash Quality ↑
70

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 18 years · 69 quarters